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Abbreviations
PA primary aldosteronism
FH familial hyperaldosteronism
APA aldosterone-producing adenoma
MR mineralocorticoid receptor.
Primary aldosteronism (PA) is the clinical manifestation of a heter-
ogeneous group of adrenal disorders that are characterized by an 
excessive production of aldosterone, which becomes relatively in-
dependent of the angiotensin-renin system regulation. Over time, 
sustained levels of aldosterone lead to increased blood pressure 
and elevated potassium excretion, therefore patients with PA are 
hypertensive, in many cases hypokalemic, and at higher risk of 
stroke, renal complications, metabolic and cardiovascular mortal-
ity than patients with essential hypertension. Once classified as a 
rare disease, PA is now considered the most common cause of en-
docrine hypertension, with an estimated prevalence of about 4–6 % 
in the general population with hypertension and up to 10–20 % in 
the subset of patients with resistant hypertension [1–3].
Most diagnosed cases of PA are sporadic and are mainly caused by 
aldosterone overproduction by both adrenal glands (bilateral adrenal 
hyperplasia) or by unilateral aldosterone-producing adenomas (APA). 
Other causes include unilateral hyperplasia and very rarely, adreno-
cortical carcinomas. In some cases, PA affects several members of the 
same family in the inherited or familial forms of hyperaldosteronism 
(FH). Current guidelines recognize three well established types of FH, 
namely FH-I to FH-III [4], however data from genetic analyses reveal a 
more complex situation, with at least 4 different inheritable forms of 
PA and possibly still more yet to be discovered.
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AbsTR AcT
Primary aldosteronism is a common cause of endocrine hyper-
tension. It results from the excess production of aldosterone 
by the adrenal cortex and is related to increased morbidity and 
mortality. Most cases of PA are sporadic but inherited patterns 
of the disease have been reported in the literature. Four forms 
of familial hyperaldosteronism (FH-I- FH-IV) are currently rec-
ognized, and the genetic basis has been clarified in recent years. 
In FH-I patients, aldosterone excess is produced by a CYP11B1/
CYP11B2 fusion gene and it is suppressed by glucocorticoid 
treatment. FH-II is caused by mutations in the inwardly rectify-
ing chloride channel CLCN2. FH-III is caused by mutations in 
KCNJ5, a gene coding for an inward rectifier K +  channel and 
mutations in the T-type calcium channel subunit CACNA1H 
cause FH-IV. In this review we summarize the knowledge on 
inherited forms of primary aldosteronism, the genetic altera-
tions that cause them and the implications it may have for the 
classification. Based on current evidence, we propose the term 
“familial hyperaldosteronism” to refer only to inherited forms 
of primary aldosteronism with a known genetic basis.
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Genes Associated With Inherited Forms of PA
The genetics of PA has remained obscure for a long time. Although 
infrequent, the early onset and the heritability favored the study of 
familial PA as an approach to understand the pathophysiology of the 
more common sporadic forms. The identification of the first genet-
ic alteration causative for a particular subtype of PA by linkage anal-
ysis on affected relatives, the chimera CYP11B1/CYP11B2[5], was an 
outstanding discovery but subsequent investigation quickly revealed 
that it was not present in sporadic forms [6, 7]. The failure to find new 
causative genes and the introduction of next generation sequenc-
ing techniques turned the focus to sporadic patients.
Now that hundreds of APAs have been sequenced, it is well 
known that KCNJ5, CACNA1D, ATP1A1 and ATP2B3 genes are mu-
tated in about 50 % of adenomas (reviewed in [8] and [9]) and that 
ion channels and pumps exert an important role on aldosterone 
signaling through the control of Ca2 +  influx [10]. Following the trend 
of next generation sequencing of sporadic cases, the study of pa-
tients with early-onset PA has uncovered that some of those genes 
also exert an important role in inherited forms. Thus, KCNJ5 ger-
mline mutations cause FH-III,  CACNA1H mutations have been found 
in families with FH-IV and de novo germline mutations in CACNA1D 
have been reported in patients with early onset of PA, seizures and 
neurologic abnormalities (PASNA). In addition, two recent studies 
in patients with early-onset PA have shown mutations in CLCN2 as-
sociated with FH-II. ▶Table 1 summarizes the genes associated with 
PA and the main clinical features and ▶Fig. 1 depicts the molecular 
mechanisms.
CYP11B1/CYP11B2 chimera: familial 
hyperaldosteronism type I (FH-I)
FH-1 was first reported in 1966 by Sutherland and colleagues [11]. 
They reported two hypertensive relatives, a father and a son, with 
a condition that mimicked the symptoms of sporadic PA (increased 
aldosterone, low renin activity and hypokalemia) but with the par-
ticularity of suppression of aldosterone production by a 2 mg/day 
dexamethasone treatment. Thus FH-I is often referred to as gluco-
corticoid-remediable aldosteronism (GRA). The basis of the gluco-
corticoid suppression was discovered in 1992, after linkage analy-
sis identified the genetic cause as a chimeric fusion on chromosome 
8 containing an unequal recombination between the highly homol-
ogous genes CYP11B1 (11-β-hydroxylase) and CYP11B2 (aldoster-
one synthase) [5]. The exact point of cross-over can be different in 
each reported family but always contains the promoter and the first 
exons of CYP11B1 and most of the coding region of CYP11B2, 
 resulting in an enzyme with aldosterone synthase activity with 
▶Table 1 Germline mutations associated with primary aldosteronism.
Germline alteration Biological effect clinical manifestation Treatment Pattern of heritability
CYP11B1/CYP11B2 
chimeric fusions
Aldosterone synthase 
inducible by ACTH 
stimulation
Glucocorticoid-suppressible 
hyperaldosteronism (FH-I)
Low dose of dexamethasone, MR 
antagonists as second line
Autosomal dominant
CLCN2 mutations Increased Cl −  efflux FH-II MR antagonists Autosomal dominant, 
incomplete penetrance
KCNJ5 mutations Reduced K +  selectivity 
and increased Na +  
influx
FH-III MR antagonist if mild, adrenalec-
tomy if severe
Autosomal dominant
CACNA1H mutations Increased Ca2 +  entry FH-IV Not standardized. No control 
observed under spironolactone 
treatment or unilateral adrenalec-
tomy
Autosomal dominant, low 
penetrance
CACNA1D mutations Increased Ca2 +  entry PA associated with seizures and 
neurological abnormalities 
(PASNA)
MR antagonist, adrenalectomy if 
lateralized
Autosomal dominant not 
likely to be inherited
ARMC5 mutations Loss of ARMC5 
expression/function
Apparently sporadic, possible 
predisposition to PA
Data not available Autosomal dominant, 
incomplete penetrance
PA, primary aldosteronism; FH, Familial hyperaldosteronism; MR, mineralocorticoid receptor
FH-III
FH-IV
↑ALDOSTERONE
↑Ca2+
Depolarisation
FH-II
Cl–
↓Cl– ↑Na+
Na+
ACTH
Ca2+
FH-I
Kir3.4
(KCNJ5)
ClC2
(CLCN2)
Cav3.2
(CACNA1H)
CYP11B2
CYP11B2CYP11B1/
chimera
▶Fig. 1 Genetic causes of familial hyperaldosteronism. Summary 
of the known molecular mechanisms that lead to familial hyperaldo-
steronism types I to IV. FH-I is produced by an asymmetrical recom-
bination between CYP11B1 and CYP11B2, resulting in the expression 
of a chimeric enzyme under the control of ACTH stimulation. FH-II is 
caused by germline mutations in the chloride channel CLCN2 that 
decrease intracellular Cl − . FH-III is produced by germline mutations 
in KCNJ5 that affect the selectivity of the channel, allowing Na +  
conductance. Both reduction of intracellular Cl −  and increase in Na +  
cause plasma membrane depolarization and open voltage-gated 
Ca2 +  channels, elevating cytosolic Ca2 + . FH-IV is caused by germline 
mutations in CACNA1H that facilitate Ca2 +  entry. In all cases, in-
crease of intracellular Ca2 +  triggers CYP11B2 transcription and aldos-
terone synthesis.
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 expression under the control of the adrenocorticotropic hormone 
(ACTH) instead of angiotensin II and potassium. As a consequence, 
aldosterone synthase is expressed in the zona fasciculata rather 
than in the zona glomerulosa, resulting in the ectopic production 
of aldosterone and the production of the hybrid steroids 18-oxo-
cortisol and 18-hydroxycortisol [5, 12].
FH-I is considered as a rare subgroup of PA that represents less 
than 1 % of all cases, increasing to 3 % in children with hypertension 
[13–15]. It is characterized by the development of bilateral adre-
nal hyperplasia, occasionally adrenal nodules, with variable clinical 
and biochemical features [14, 16]. FH-I follows an autosomal dom-
inant inheritance pattern and is generally associated with early 
onset severe hypertension and an increased risk of stroke; howev-
er, different degrees of severity have been reported, including cases 
of mild hypertension and normotensive individuals [16–18].
The Endocrine Society guideline recommends testing for FH-I 
in patients with an early onset of PA ( < 20 years old) and in those 
with a familial occurrence of PA or stroke at a young age ( < 40 years 
old) [4]. The correct diagnosis is clinically relevant because aldos-
terone excess can be controlled successfully through glucocorti-
coid therapy [19]. Prior to the existence of targeted molecular tests, 
the diagnosis was made through clinical and biochemical evalua-
tion. Dexamethasone suppression of aldosterone and levels of hy-
brid steroids were used to establish a diagnosis of FH-I [20, 21] until 
the introduction of techniques to specifically detect the presence 
of the CYP11B1/CYP11B2 chimeric gene either by Southern blot-
ting or by the recommended technique employing a long-chain 
PCR amplification [4, 21–23].
In patients with FH-I aldosterone production is abrogated under 
glucocorticoid treatment, and partial suppression of ACTH is enough 
to correct the hypertension associated with FH-I. Accordingly, low 
doses of dexamethasone are recommended to achieve normoten-
sion whilst preventing undesired cushingoid features [19]. Mineralo-
corticoid receptor antagonists (spironolactone or eplerenone) can 
be used as a second line of therapy to block possible non-genomic 
effects of aldosterone on target organs, or in children to avoid pos-
sible side effects of dexamethasone treatment [24]. If target blood 
pressure levels are not reached by low dose dexamethasone, addi-
tional standard antihypertensive medication can be added (i. e. cal-
cium antagonists, beta-blockers).
CLCN2: familial hyperaldosteronism type II (FH-II)
FH-II was first described by Gordon et al. in 1991, a year before the 
genetic cause of FH-I was published. They described 6 relatives from 
3 independent affected families who presented with PA caused by 
either APA or BAH and a lack of suppression of aldosterone produc-
tion by fludrocortisone or dexamethasone [25]. Several families were 
reported by the same group shortly thereafter [26, 27].
Until very recently, the genetic cause of FH-II remained elusive. 
Early targeted genetic studies showed a lack of mutations on genes 
related to steroidogenic production or tumorigenesis, such as 
CYP11B2, the angiotensin receptor AT1R or TP53. Later on, genet-
ic linkage analysis of non-related families highlighted a locus at 
chromosome 7p22 that segregated with the disease in some fam-
ilies, but not in all cohorts [28–30]. However both targeted se-
quencing of different genes in that region as well as next-genera-
tion sequencing of the complete locus failed to find mutations 
[29, 31–33]. Scholl and colleagues analyzed the genomic DNA by 
exome sequencing of three members from one of the FH-II fami-
lies described by Stowasser et al. in 1992 [27]. The authors identi-
fied a germline mutation in the gene CLCN2 that segregated with 
the disease. This variant, p.Arg172Gln, was confirmed subsequent-
ly in five additional family members, four of them with aldoster-
one-to-renin ratio suggestive of PA [34]. Because the discovery 
family was one of the first families diagnosed with FH-II, Scholl  et al. 
proposed the use of that term only for inherited PA due to CLCN2 
mutations [34]. The authors also reported the same mutation in 
three additional unrelated individuals, as well as rare germline 
CLCN2 variants (p.Met22Lys, p.Tyr26Asn, p.Lys362del and 
Ser865Arg, with allele frequencies below 10 − 5) in four additional 
unrelated patients [34]. Simultaneously, Fernandes-Rosa and col-
leagues identified another germline CLCN2 mutation in a 9-years-
old patient by exome-sequencing sequencing of genomic DNA 
from 12 patients with young-onset hypertension and PA. In that 
case, p.Gly24Asp was a de novo mutation. Two additional variants 
were found in two cases from a cohort of 100 patients with idio-
pathic bilateral adrenal hyperplasia (p.Arg66Gln and p.Pro48Arg, 
with minor allele frequencies of 3 × 10 − 5 and 1.7 × 10 − 4, respec-
tively) [35]. Both studies showed that CLCN2 mutations were re-
lated to PA diagnosed at early age and absent in patients with es-
sential hypertension [34, 35].
CLCN2 gene is located in chromosome 3q27 and encodes the 
inwardly rectifying chloride channel ClC2, a member of the CLC 
voltage-gated Cl −  channels family. ClC2 is broadly expressed in 
mammalian cells, especially in brain, gut, kidney, heart and liver 
[36]. Mutations inactivating CLCN2 cause leukodystrophy, in some 
cases with azoospermia, and Clcn2 knockout mice also develop 
early postnatal retinal degeneration [37–39]. Scholl et al. and Fer-
nandes-Rosa et al. have shown that ClC2 is also expressed in the 
adrenal gland. Furthermore, germline mutations that associate 
with PA result in gain of function of the Cl −  channel, causing an ef-
flux of Cl −  ions that leads to the depolarization of the plasma mem-
brane, the consequent opening of voltage-gated Ca2 +  channels, 
the accumulation of cytosolic Ca2 +  and the activation of CYP11B2 
transcription [34, 35].
Before the recent discovery of CLCN2 mutations, screening for 
FH-II was based on the diagnosis of PA in at least two first-degree 
members of the same family and the absence of known germline 
mutations. Thus, this familial form was thought to be the most 
prevalent, representing about 3–6 % of all PA cases [11, 54]. Nev-
ertheless, Korah and Scholl pointed out that this estimation may 
be misleading: considering the prevalence of hypertension in the 
general population (about 30 %) and the PA prevalence in the gen-
eral population with hypertension (about 5 %), the probability for 
an index case to have at least a first-degree relative with PA just by 
chance is ~5.9 % [40]. Accordingly, it is likely that some of the de-
scribed FH-II families were in fact coincidental cases of sporadic id-
iopathic PA. This observation may explain, at least partially, the ap-
parent heterogeneity reported in previous studies. To avoid con-
fusion, and to base the classification on a simple and transparent 
genetic basis similar to other genetic diseases, we propose to use 
the term “familial hyperaldosteronism” only when an inherited ge-
netic cause is established.
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Following this reasoning, the number of true FH-II families is 
probably much lower than previously reported. In their studies, 
Scholl et al. and Fernandes-Rosa et al. identified CLCN2 mutations 
in about 10 % of cases with young-onset PA without known ger-
mline mutations and 2 % with bilateral adrenal hyperplasia [34, 35] 
suggesting a lower frequency than previous estimates. Further ef-
forts are needed to determine the actual prevalence of FH-II.
KCNJ5: familial hyperaldosteronism type III (FH-III)
FH-III was described by Geller et al. in three family members, a father 
and his two young daughters, who developed hyperaldosteronism 
with hypokalemia and severe hypertension at very early age, togeth-
er with marked bilateral adrenal enlargement. High levels of the hy-
brid steroids 18-oxocortisol and 18-hydroxycortisol were detected 
in urine samples but the disorder was distinguishable from FH-I by 
the glucocorticoid resistance of the hyperaldosteronism and the lack 
of suppression of aldosterone production on dexamethasone sup-
pression testing. Hypertension and hypokalemia were refractory to 
medical therapy and disease control was achieved only after bilater-
al adrenalectomy [41]. Careful examination of the adrenals revealed 
disorganized zonation, a reduction in the thickness of the zona glo-
merulosa, an enlarged zona fasciculata and the presence of cells that 
co-express enzymes which are usually expressed in distinct zones, 
such as CYP11B1 and CYP11B2 and also CYP17 and CYP11B2. The 
co-expression of CYP17 and  CYP11B2 is the likely basis for the pro-
duction of hybrid steroids [12, 41, 42].
It was not until 2011 that the genetic etiology of FH-III was clar-
ified. By means of exome sequencing, Choi et al. identified a hete-
rozygous germline mutation located on chromosome 11q24 in the 
patients reported by Geller and colleagues, as well as in sporadic 
cases of PA [43]. The affected gene was KCNJ5, which codes for the 
G-protein-activated inward rectifier K +  channel 4 (Kir3.4). This pro-
tein forms homo- and heterotetramers with other Kir family mem-
bers to constitute the functional G-protein-activated inwardly rec-
tifying potassium channel, which contributes to the control of 
membrane polarity in the zona glomerulosa [44]. The mutation 
identified in Geller’s cases (p.Thr158Ala) was associated with a loss 
in K +  selectivity and an increased influx of Na +  into the cytoplasm, 
leading to membrane depolarization and the elevation of intracel-
lular Ca2 +  levels, which ultimately triggers aldosterone production 
through the activation of Ca2 + -related signaling pathways [45].
Since the link between inherited PA and KCNJ5, several familial 
cases with different mutations in that gene have been published, 
mostly in or next to the selectivity filter [46–51], and the term FH-III 
is used for familial cases with PA due to germline KCNJ5 mutations, 
regardless of the phenotype. Indeed, the clinical features of the af-
fected cases vary all along the PA spectrum, from mild and treat-
ment-responding forms to severe PA with progressive disease, in-
cluding symptoms mimicking diabetes insipidus and a recent report 
showing development of Cushing’s syndrome in one patient with 
FH-III [50]. This variability seems to be dependent on the type of the 
grounding KCNJ5 mutations, among other factors[46]. Thus, 
p.Gly151Glu mutations seem to associate with a milder phenotype 
and stable disease [46, 49], while p.Gly151Arg, p.Thr158Ala, 
p.Ile157Ser and p.Tyr152Cys mutations relate to a more severe hy-
peraldosteronism [52]. Other infrequent germline alterations of 
KCNJ5 (some of them de novo) and a rare non-synonymous SNP 
(rs7102584) have been described. The mutation p.Glu145Gln af-
fects a salt bridge close to the selectivity filter, while mutations p.Ar-
g52His, p.Glu246Lys, p.Gly247Arg and the SNP Glu282Gln were lo-
cated elsewhere in the protein [53, 54]. Except of the p.Gly247Arg, 
those variants altered channel functionality and increased aldoster-
one production compared with the wild-type protein.
The prevalence of FH-III has not been established systematical-
ly but it is estimated to be present in  < 1 % of all PA cases [47]. The 
Endocrine Society guideline recommends testing for FH-III by se-
quencing peripheral blood for mutations in KCNJ5 in those patients 
with a very early onset of PA [4]. Because of the variety of presen-
tations, treatment for FH-III depends on the severity of the disease. 
Milder cases can be well controlled with spironolactone, while ad-
renalectomy is currently the best option to treat resistant forms 
successfully [52].
CACNA1H: familial hyperaldosteronism type IV 
(FH-IV)
FH-IV was reported by Scholl and coworkers in a cohort of 40 pa-
tients diagnosed with PA in early childhood (at age 10 years or 
below) and without mutations in any common known PA genes. By 
whole exome sequencing analysis, a recurrent mutation in the gene 
CACNA1H was identified in five unrelated patients, four males and 
one female [55]. Shortly thereafter Daniil et al. reported the pres-
ence of different mutations in the same gene in two unrelated in-
dividuals who were diagnosed originally with FH-II, as well as an 
adult male case with a de novo mutation and an adult female pa-
tient with an APA and a germline mutation in the same gene [56]. 
Patients showed no apparent signs of seizures, cardiac arrhythmia 
or muscular or neurological alterations that have been commonly 
linked to other disorders caused by CACNA1H germline mutations 
or by another Ca2 +  channel subunit, CACNA1D[57], although one 
of the patients was diagnosed with minor mental retardation and 
multiplex developmental disorder [56]. So far, eight families with 
FH-IV have been described.
The gene CACNA1H is located on chromosome 16 and encodes 
the T-type (low voltage activated) calcium channel subunit Cav3.2. 
This protein is expressed in the zona glomerulosa [55, 57] and, as 
other Cav3 family members, is activated by small depolarizing 
changes in the membrane potential [58]. Germline CACNA1H mu-
tations have been associated with several diseases including epi-
lepsy, autism and amyotrophic lateral sclerosis [59–61]. In their 
studies, Scholl et al. and Daniil et al. reported six index cases with 
germline mutations affecting the residue Met1549, four cases with 
an inherited p.Met1549Val substitution, one with a de novo 
p.Met1549Val and one with a de novo p.Met1549Ile [55, 56]. This 
residue is located in the transmembrane segment S6 of the repeat 
domain III of Cav3.2, forming a conserved methionine-phenylala-
nine-valine (MFV) tripeptide motif that controls channel inactiva-
tion [62]. Functional experiments have demonstrated that muta-
tions in Met1549 result in a decrease in the inactivation of Cav3.2 
compared with the wild-type protein. As a consequence, the chan-
nel remains open longer with an increase in Ca2 +  influx, which ac-
tivates the expression of CYP11B2 and other steroidogenic genes 
[55, 56, 63]. Noteworthy, treatment with a T-type calcium channel 
blocker abrogated the aberrant CYP11B2 activation and aldoster-
one production in HAC15 cells overexpressing Cav3.2 p.Met-
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1549Val mutant channels, which indicates that drugs of this class 
could be useful in the treatment of patients with FH-IV [63].
In their study, Daniil et al. reported 3 additional variants: p.Ser-
196Leu, located in the voltage sensor region on the transmem-
brane segment S4 of the repeat domain I of Cav3.2, in a male pa-
tient and his sister; p.Pro2083Leu, located in the C-terminal cyto-
plasmic domain, in another index case and his brother; and 
a de novo p.Val1951Glu, also located in the C-terminal domain, in 
a patient with an APA (no familial history available). All mutations 
altered Cav3.2 function and enhanced aldosterone production to 
a greater or a lesser degree [56].
Although further studies are needed, available data suggests 
that FH-IV may be a rare form of FH. It follows an autosomal dom-
inant pattern of heritability but with reduced penetrance, particu-
larly in adults. Indeed, some family members with mutations in 
p.Met1549 were affected with resistant hypertension and PA and 
others displayed milder or even normotensive phenotype, suggest-
ing that other factors, such as genetic modifiers, somatic mosai-
cism or the age of the patient, could restrain the gene defect [55]. 
The type and location of the mutation may also play a role in the 
pathophysiology of FH-IV, resembling what has been described for 
KCNJ5 [46]. This fact could also explain the differences on disease 
presentation among the index cases: some of them were florid 
cases of PA at their early childhood but without evidence of adre-
nal hyperplasia; while other patients were diagnosed in their adult-
hood, nodularity was detected bilaterally in one patient and an APA 
was diagnosed in another case [55, 56].
Other Germline Mutations Described in 
Patients With PA
Although not considered established causes of FH, it is worth men-
tioning that germline mutations in CACNA1D and ARMC5 have 
been reported in patients with PA.
CACNA1D codes for Cav1.3, an L-type (high-voltage activated) 
Ca2 +  channel subunit and is recurrently mutated in about 10 % of 
sporadic APAs. Most sporadic alterations cause gain of function and 
lead to an increase of Ca2 +  influx and the consequent overproduc-
tion of aldosterone [57]. Recently, Scholl and coworkers identified 
two de novo mutations in two unrelated cases diagnosed with 
PASNA (PA associated with seizures and neurological abnormali-
ties) [57]. Although the severe comorbidities of affected individu-
als make the heritability of PASNA very unlikely, it is tempting to 
speculate that other CACNA1D mutations that cause a milder phe-
notype could be involved in a still not described familial form of PA, 
in the same way that has been proposed for KCNJ5 in FH-III.
ARMC5 encodes an apoptosis regulator that belongs to the 
armadillo/β-catenin-like repeat superfamily. Inactivating muta-
tions in ARMC5 have been reported in both sporadic and inherited 
primary bilateral macronodular hyperplasia, an adrenocortical dis-
ease associated with cortisol excess [64–66]. Mutated ARMC5 pro-
motes cell survival and cortisol production in vitro [64, 65]. Inter-
estingly, germline ARMC5 variants have been identified in patients 
with apparent sporadic cases of PA [67, 68], suggesting a possible 
inherited predisposition for nodule formation prior to the hormo-
nal-producing phenotype. Nevertheless, the deleterious effect of 
those mutations is still quite unclear, as most variants are predict-
ed to be unlikely pathogenic [69]. Thus, further studies must con-
firm or refuse the possible role of ARMC5 germline mutations in 
the etiology of PA.
New Genes, New Phenotypes - We Need a 
New Classification!
In the recent years, our knowledge on inherited forms of PA has 
progressed substantially [8, 70]. FH classification has evolved from 
two clinically distinct forms (FH-I and FH-II) described in the previ-
ous Endocrine Society guideline [71] to at least four genetically de-
fined types in which patients are grouped based on the presence 
of causative mutations (FH-I/CYP11B1/B2 chimera, FH-II/CLCN2, 
FH-III/KCNJ5 and FH-IV/CACNA1H). Despite substantial scientific 
advances, some questions remain unanswered. Firstly, the clinical 
heterogeneity within groups of FH related to variable disease pres-
entation and incomplete penetrance suggest a possible modula-
tion of genetic causes by non-genetic factors. This hypothesis could 
explain why relatives with germline mutations are apparently 
asymptomatic. Secondly, the prevalence of FH-II and FH-IV fami-
lies is still uncertain. Evidence suggests that the frequency of CLCN2 
and CACNA1H mutations is low. Thus, extensive studies are need-
ed to determine the actual prevalence and the clinical relevance of 
these subtypes. Lastly, it must be elucidated whether apparent fa-
milial cases without known mutations truly follow inherited pat-
terns of PA. Further next-generation sequencing studies will gain 
insight into the molecular causes of PA and probably contribute to 
the establishment of new FH types. Misclassification of sporadic PA 
cases as FH should be avoided. For that reason, we discourage the 
use of non-genetic criteria for the screening and classification of 
FH and propose the term “familial hyperaldosteronism” only to be 
used when known germline mutations are detected.
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